Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells

Lysine-specific demethylase 1 (LSD1) has been recognized as a potential therapeutic target for acute myeloid leukemia (AML). Herein, we identified a novel LSD1 inhibitor, JL1037, via Computer Aided Drug Design technology. JL1037 is a potent, selective and reversible LSD1 inhibitor with IC50s of 0.1...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuang, Lu, Wenting, Li, Shouyun, Li, Saisai, Liu, Jia, Xing, Yuanyuan, Zhang, Shuzu, Zhou, Joe Zhongxiang, Xing, Haiyan, Xu, Yingxi, Rao, Qing, Deng, Chengjun, Wang, Min, Wang, Jianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458257/
https://www.ncbi.nlm.nih.gov/pubmed/28404874
http://dx.doi.org/10.18632/oncotarget.16650

Ejemplares similares

Ejemplares similares